SPP1 and glioblastoma: Higher expression of SPP1 was an unfavorable prognosticator for patients with CESC (HR = 1.66, 95%CI = [1.02, 2.72], p = 0.043), GBM (HR = 1.55, 95% CI = [1.08, 2.21], p = 0.016), LIHC (HR = 1.88, 95% CI = [1.29, 2.75], p = 0.001), LUAD (HR = 1.50, 95% CI = [1.11, 2.02], p = 0.008), and had a trend of unfavorable survival in LUSC (HR = 1.29, 95% CI = [0.98, 1.70], p = 0.068), PAAD (HR = 1.47, 95% CI = [0.97, 2.23], p = 0.070).